You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

What is the current cost of asthma therapies?

Compare the 30 day acquisition cost of Relvar® Ellipta®  with other ICS/LABA combinations[1]

List price: ICS/LABA combinations for the treatment of asthma graph

Please note: ICS/LABA combinations are categorized here as per the latest BTS/SIGN guideline[2]. This information is sensitive to price changes; drug costs and information for currently available asthma therapies were last updated in April 2017 [1]. Prescribing decisions should not be based on cost alone. You should refer to the SPC of each medicine for further information such as indications, contraindications, precautions and adverse events[3].

What potential cost savings could the Ellipta portfolio offer in your locality?

To discuss potential cost savings available in your locality, please contact us via the ‘HOC: on-Demand’.
 

Download the 30 day drug acquisition cost information for asthma medicines

 

Download the 30 day drug acquisition cost information for asthma medicines

References:

  1. Monthly Index of Medical Specialities Online. Available at: http://www.mims.co.uk/ [Accessed April 2017]
  2. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma 2016. Available at: https://www.brit-thoracic.org.uk [Accessed April 2017]
  3. Summary of Product Characteristics. Available at: http://medicines.org.uk/emc/ [Accessed April 2017]

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Relvar, Ellipta, Seretide, Accuhaler and Evohaler are registered trademarks of the GlaxoSmithKline group of companies